Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prognosis Biomarker of AD”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Not applicableNot Yet RecruitingNCT06825663
What this trial is testing

Marker of Brain Insulin Resistance in AD Prognosis

Who this might be right for
Prognosis Biomarker of ADMild Cognitive ImpairmentBrain Insuline Resistance
Central Hospital, Nancy, France 122
Large-scale testing (Phase 3)Ended earlyNCT01931566
What this trial is testing

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Who this might be right for
Mild Cognitive Impairment Due to Alzheimer's Disease
Takeda 3,494
Not applicableLooking for participantsNCT06803784
What this trial is testing

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

Who this might be right for
Parkinson DiseaseAmyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia (FTD)+1 more
Neuromed IRCCS 110